Mutual of America Capital Management LLC Sells 922 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Mutual of America Capital Management LLC decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,300 shares of the medical equipment provider’s stock after selling 922 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Intuitive Surgical were worth $18,478,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Intuitive Surgical in the 4th quarter worth $1,313,238,000. WCM Investment Management LLC bought a new position in Intuitive Surgical in the fourth quarter worth about $575,536,000. International Assets Investment Management LLC lifted its position in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Intuitive Surgical by 111.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,285,565 shares of the medical equipment provider’s stock valued at $513,056,000 after buying an additional 678,375 shares in the last quarter. Finally, Alphinity Investment Management Pty Ltd grew its position in shares of Intuitive Surgical by 113.2% in the 4th quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after buying an additional 677,455 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the transaction, the director now owns 25,319 shares in the company, valued at $9,385,753.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. Over the last quarter, insiders sold 17,956 shares of company stock worth $6,927,011. Company insiders own 0.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several analyst reports. Stifel Nicolaus lifted their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Robert W. Baird decreased their price target on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Citigroup boosted their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Finally, Evercore ISI increased their price objective on shares of Intuitive Surgical from $385.00 to $425.00 and gave the company an “in-line” rating in a research report on Tuesday, July 2nd. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $404.79.

Intuitive Surgical Stock Up 0.2 %

Shares of ISRG traded up $0.77 during mid-day trading on Monday, reaching $444.53. The company had a trading volume of 1,280,648 shares, compared to its average volume of 1,512,717. The stock has a market capitalization of $157.67 billion, a P/E ratio of 80.24, a PEG ratio of 5.73 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $448.10. The stock has a 50 day moving average of $411.61 and a two-hundred day moving average of $388.14.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the company earned $1.00 EPS. The business’s revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.